Zynerba Pharmaceuticals, INC.
health/governmental assistance before FDA
Based in PA
AI Overview
With $400K in lobbying spend across 15 quarterly filings, Zynerba Pharmaceuticals, INC is an active lobbying client. Their lobbying covers 3 issue areas. Active from 2020 to 2023.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2020 | $45K |
| 2021 | $165K |
| 2022 | $80K |
| 2023 | $110K |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that Zynerba Pharmaceuticals, INC. disclosed contacting in their lobbying filings.
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Government Issues, Health Issues, Pharmacy
Assist in the development & approval process before the FDA of Zynerba's lead therapeutic for the potential treatment of behavioral symptoms associated with Fragile X Syndrome.
Brief key House & Senate Members and/or appropriate staff on need and justification for this product. Secure letter of support for applications from key House & Senate Members.
Support Zynerba and its partners, and any other of its contractors in its process before the FDA; Troubleshoot inevitable issues and eligibility hurdles to ensure the project is considered for approva
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.